Clinical trials: Soft Tissue Neoplasm
Mesenchymal Chondrosarcoma
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
- Trial name
- ISG-MCS (NCT04305548)
- Testing
- Trabectedin
- Where
- 7 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Italian Sarcoma Group
Bone and Soft Tissue Tumors
Molecular and Clinical Studies of Bone and Soft Tissue Tumors
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope.
- Trial name
- NCT07822204
- Where
- Sweden
- Volunteers
- 50,000 people
- Sponsor
- Karolinska Institutet
Soft Tissue Neoplasms
Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans
Retrospective review of clinical outcome of pediatric Dermatofibrosarcoma Protuberans (PDFSP) after active invitation
- Trial name
- NCT00173355
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Uterine Fibroids (UF), Microwave Ablation
Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the Treatment of Uterine Fibroids: A Prospective, Multicenter Study
Uterine fibroids are the most common benign tumors in women of reproductive age, with a prevalence of 20%-50%, often causing menorrhagia, anemia, pelvic pain, and pressure symptoms that markedly impair quality of life.
- Conditions
- Uterine Fibroids (UF), Microwave Ablation, Ultrasound
- Trial name
- NCT07754877
- Testing
- Microwave ablation combined with chemical ablation, Microwave ablation
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Peking University Aerospace Center Hospital
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Sarcoma
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and…
- Trial name
- MAGNATE-S (NCT07359053)
- Testing
- Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib, Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai 6th People's Hospital
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Sarcoma
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01426945
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 77 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782145
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Tufts Medical Center
Alveolar Soft-part Sarcoma
A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
The study is a two-arm, randomised, double-blind, international, multi-centre phase II trial of cediranib in Alveolar Soft Part Sarcoma (ASPS).
- Trial name
- CASPS (NCT01337401)
- Testing
- Cediranib
- Where
- 11 sites in Australia, Spain and 1 more
- Volunteers
- 36 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioma, Rhabdomyosarcoma
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
This study proposes to treat patients with the combination of erlotinib and temozolomide. Patients with relapsed, recurrent, refractory, or high risk malignancies whose tumors possess a non-synonymous mutation in EGFR, ERBB2, or…
- Conditions
- Glioma, Rhabdomyosarcoma, Osteosarcoma, Medulloblastoma
- Trial name
- NCT02689336
- Testing
- Erlotinib, Temozolomide
- Sponsor
- Washington University School of Medicine
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue.
- Trial name
- NCT00579566
- Testing
- Specimen protocol
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care
The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and…
- Trial name
- NCT04300257
- Where
- 8 sites in Switzerland
- Volunteers
- 600 people
- Sponsor
- Kantonsspital Winterthur KSW
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumors, Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not…
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT04337177
- Testing
- VAL-413, Temozolomide
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Valent Technologies, LLC
Burn Injury, Soft Tissue Injury
Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
The purpose of this study is the evaluation of the safety of autologous tissue-engineered dermal substitutes "denovoDerm" (first arm) and dermo-epidermal skin substitutes "denovoSkin" (second arm) transplanted onto the wound bed…
- Conditions
- Burn Injury, Soft Tissue Injury, Skin Necrosis, Scars
- Trial name
- NCT02145130
- Testing
- denovoDerm, denovoSkin
- Where
- 2 sites in Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Ewing's Sarcoma, Osteosarcoma
HGS-ETR2 to Treat Children With Solid Tumors
Background HGS-ETR2 is a monoclonal antibody, produced in the laboratory from human genes. HGS-ETR2 targets a protein called the TRAIL receptor that is located on the surface of some tumor cells.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
- Trial name
- NCT00428272
- Testing
- Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.